Search

Displaying results 3321 - 3330 of 3588 in total
  1. Drug

    Osunprotafib

    go.drugbank.com/drugs/DB21547
    Investigational

    The usage of the INN stem '-protafib' in the name indicates that Osunprotafib is a human protein tyrosine phosphatase (HPTP) inhibitor.

  2. Drug

    Zelicapavir

    go.drugbank.com/drugs/DB21662
    Investigational

    The usage of the INN stem '-capavir' in the name indicates that Zelicapavir is a viral capsid and nucleocapsid inhibitor.

  3. Drug

    Zoracopan

    go.drugbank.com/drugs/DB21702
    Investigational

    The usage of the INN stem '-copan' in the name indicates that Zoracopan is a complement receptor antagonist/complement inhibitor.

  4. Drug

    Influenza A virus A/Darwin/6/2021 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16922
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  5. Drug

    Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16925
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  6. Drug

    Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen

    go.drugbank.com/drugs/DB17995
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  7. Drug

    Influenza A virus A/Georgia/12/2022 CVR-167 (H1N1) Antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB17996
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  8. Drug

    Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB17998
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  9. Drug

    Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB18661
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  10. Drug

    Influenza A virus A/Sydney/1304/2022 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB19321
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes